TERMINATION AGREEMENT by and between FIBROGEN, INC. and ASTRAZENECA AB Dated as of February25, 2024Termination Agreement • May 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations
This Termination Agreement (this “Termination Agreement”) is made and effective as of February 25, 2024 (the “Termination Agreement Effective Date”) by and between AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with offices at Pepparedsleden 1, SE-431 83 Mölndal, Sweden (“AstraZeneca”); and FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois St., San Francisco, California 94158, United States (“FibroGen”) (each of AstraZeneca and FibroGen, a “Party”, and collectively, the “Parties”).
AMENDMENT No. 1 TO THE EXCLUSIVE LICENSE AND OPTION AGREEMENTExclusive License and Option Agreement • May 6th, 2024 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 1 to the Exclusive License and Option Agreement (this “Amendment No. 1”) is entered into as of February 14, 2024 (the “Amendment No. 1 Effective Date”) by and among HiFiBiO Inc., a Delaware corporation having an address at 237 Putnam Ave. Cambridge, MA 02139(“HFB US”), and FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois St., San Francisco, CA 94158 (“FibroGen”).
